GET DAILY SIGNALSHeartFlow (HTFL) Stock Jumps +92.9% in 30 Days on Strong Q2 Results
Key Takeaways
- HeartFlow shares rose approximately 92.9% over the trailing 30 days, climbing from about $25.37 to roughly $48.94.
- The rally was driven by second-quarter 2026 results that beat expectations and a meaningful increase to full-year revenue guidance.
- Several sell-side firms raised price targets following the report, reinforcing positive sentiment toward the stock.
- The company remains unprofitable, so growth execution and continued adoption of its Plaque Analysis product remain central to the investment case.
HeartFlow (HTFL) Company Overview and Market Position
HeartFlow, Inc. is a commercial-stage medical technology company based in San Francisco that uses artificial intelligence and advanced computational fluid dynamics to deliver non-invasive solutions for diagnosing and managing coronary artery disease (CAD). Its HeartFlow One platform builds a personalized 3D model of a patient's coronary arteries from a single coronary computed tomography angiography (CCTA) image, and includes Roadmap Analysis, FFRCT Analysis, and Plaque Analysis software. The company has accumulated one of the world's largest databases of annotated cardiac CT images—more than 200 million images—and has helped guide care for over 650,000 patients worldwide. HeartFlow completed its initial public offering in August 2025 and generates the large majority of its revenue in the United States. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
HeartFlow (HTFL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HTFL advanced roughly 92.9%, rising from a closing price near $25.37 in late July to about $48.94 by late August. Most of that move occurred in a matter of days after the company reported quarterly results, with shares jumping more than 35% in a single session and continuing to trade near 52-week highs afterward.
The quarterly picture tells a similar but more volatile story. Roughly three months earlier, the stock traded near $28, meaning it has gained on the order of 72% over the period. That broader trend was not linear: shares declined through much of July into the low-to-mid $20s before rebounding sharply once second-quarter results and revised guidance reset investor expectations.
What Drove HTFL Stock Price in the Last 30 Days
The primary catalyst was HeartFlow's second-quarter 2026 earnings report. Revenue rose 48% year over year to approximately $64.1 million, ahead of the consensus estimate near $56.6 million, and adjusted loss per share of $0.07 was narrower than the roughly $0.13 loss analysts had expected. Gross margin reached record levels, expanding to 83.0% on a GAAP basis and 83.3% on a non-GAAP basis.
Management also raised its full-year 2026 revenue guidance to between $246 million and $250 million, up from a prior range of $228 million to $232 million, implying roughly 40% to 42% growth, and lifted its full-year gross margin target. Analysts responded by raising price targets—Stifel moved to $45 from $40 with a Buy rating, JPMorgan raised its target to $45 from $35 with an Overweight rating, and Wells Fargo increased its target to $39 from $37. William Blair's Brandon Vazquez maintained an Outperform rating, noting the guidance increase was roughly twice the size of the earnings beat. From what I see, this level of analyst support adds meaningful weight to the recent move.
What Drove HTFL Stock Performance Over the Last Quarter
Beyond the immediate earnings reaction, the stock's three-month advance reflects a broader narrative of accelerating adoption of AI-enabled cardiac diagnostics. HeartFlow's core FFRCT business has remained durable, while Plaque Analysis has emerged as a fast-growing second revenue engine following expanded reimbursement coverage. The company also launched PCI Navigator, an AI-driven pre-procedure planning tool for interventional cardiologists, and has pointed to a substantially under-penetrated CCTA market as a source of continued growth.
Institutional participation has also increased. According to third-party data, the number of hedge funds holding HeartFlow shares rose from 16 to 25 between consecutive quarters, with combined holdings growing by more than half. At the same time, the stock remains unprofitable, and valuation has expanded alongside the rally, leaving the shares sensitive to any shortfall in adoption or reimbursement trends.
HTFL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on the pace of Plaque Analysis adoption, including the company's progress toward its target of roughly 1,200 active sites, and on whether FFRCT case volumes sustain their current growth. Reimbursement developments, new clinical data, and updates to full-year guidance will also matter, as will the company's path toward narrowing operating losses and reaching cash-flow profitability. Because the stock has re-rated sharply, execution against the raised revenue outlook and continued gross-margin expansion will be closely monitored, alongside any signs that adoption is slowing or that valuation has outrun fundamentals. I’m watching this closely as the next few quarters will test whether the momentum holds.
Exploring Tickeron’s Trending AI Robots for Additional Perspective
In my own research process, I occasionally review Tickeron’s Trending AI Robots page to see how automated strategies are performing across various tickers. It offers a focused look at top bots without requiring a full scan of every option available, which can provide a useful complement when evaluating names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
HTFL in +4.69% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HTFL advanced for three days, in 77 of 85 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Aroon Indicator entered an Uptrend today. In 48 of 62 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The 10-day RSI Indicator for HTFL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 4 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HTFL as a result. In 23 of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for HTFL turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 9 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
HTFL broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.289) is normal, around the industry mean (4.477). P/E Ratio (-16.610) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. HTFL's P/S Ratio (19.763) is slightly higher than the industry average of (6.065).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement